Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study-Reference-Cited by-同舟云学术

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

Published:2023-06 Issue: Volume:29 Page:100624
ISSN:2666-7762
Container-title:The Lancet Regional Health - Europe
language:en
Short-container-title:The Lancet Regional Health - Europe

Author:

Ray Kausik K.^ORCID,Haq Inaam,Bilitou Aikaterini^ORCID,Manu Marius C.,Burden Annie,Aguiar Carlos,Arca Marcello,Connolly Derek L.^ORCID,Eriksson Mats,Ferrières Jean,Laufs Ulrich,Mostaza Jose M.,Nanchen David^ORCID,Rietzschel Ernst,Strandberg Timo,Toplak Hermann,Visseren Frank L.J.,Catapano Alberico L.^ORCID

Publisher

Elsevier BV

Subject

Health Policy,Oncology,Internal Medicine

Reference29 articles.

1. Cardiovascular disease in Europe: epidemiological update 2016;Townsend;Eur Heart J,2016

2. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials;Mihaylova;Lancet,2012

3. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017

4. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel;Borén;Eur Heart J,2020

5. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS);Mach;Eur Heart J,2020

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug interactions in cardiology: focus on statins and their combination with other lipid-lowering drugs;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13

2. PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention;Lipids in Health and Disease;2024-09-10

3. Lipid-lowering therapy in patients with coronary heart disease: an Italian real-life survey. Results from the Survey on Risk FactOrs and CardiovascuLar secondary prEvention and drug strategieS (SOFOCLES) in Italy;Monaldi Archives for Chest Disease;2024-09-10

4. Lipid-Lowering Treatment Gaps in Patients after Acute Myocardial Infarction: Using Global Database TriNetX;Medicina;2024-09-02

5. Lifelong prevention of atherosclerotic cardiovascular disease (ASCVD) through LDL-C control - Means and cost/benefit of sustained very low lifetime LDL-C targets;American Journal of Preventive Cardiology;2024-09